Development and function of murine B cells lacking RANK

Journal of Immunology

Volumn 188, Issue 3, 2012, Pages 1201-1205

  Perlot, Thomas ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; GENETIC RECOMBINATION; HUMORAL IMMUNITY; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; MICE; MICE, KNOCKOUT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84856587339     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102063     Document Type: Article

References (26)

1. Leibbrandt, A., and J. M. Penninger. 2008. RANK/RANKL: regulators of immune responses and bone physiology. Ann. N. Y. Acad. Sci. 1143: 123-150.
2. Dougall, W. C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M. E. Tometsko, C. R. Maliszewski, et al. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev. 13: 2412-2424. (Pubitemid 29453612)
3. Kong, Y. Y., H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J. Oliveira-dos-Santos, G. Van, A. Itie, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
4. Fata, J. E., Y. Y. Kong, J. Li, T. Sasaki, J. Irie-Sasaki, R. A. Moorehead, R. Elliott, S. Scully, E. B. Voura, D. L. Lacey, et al. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50.
5. Rossi, S. W., M. Y. Kim, A. Leibbrandt, S. M. Parnell, W. E. Jenkinson, S. H. Glanville, F. M. McConnell, H. S. Scott, J. M. Penninger, E. J. Jenkinson, et al. 2007. RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204: 1267-1272. (Pubitemid 46919863)
6. Hanada, R., T. Hanada, V. Sigl, D. Schramek, and J. M Penninger. 2011. RANKL/RANK-beyond bones. J. Mol. Med. 89: 647-656.
7. Schramek, D., A. Leibbrandt, V. Sigl, L. Kenner, J. A. Pospisilik, H. J. Lee, R. Hanada, P. A. Joshi, A. Aliprantis, L. Glimcher, et al. 2010. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102.
8. Jones, D. H., T. Nakashima, O. H. Sanchez, I. Kozieradzki, S. V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C. V. Hojilla, et al. 2006. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
9. Tan, W., W. Zhang, A. Strasner, S. Grivennikov, J. Q. Cheng, R. M. Hoffman, and M. Karin. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470: 548-553.
10. Yun, T. J., P. M. Chaudhary, G. L. Shu, J. K. Frazer, M. K. Ewings, S. M. Schwartz, V. Pascual, L. E. Hood, and E. A. Clark. 1998. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40. J. Immunol. 161: 6113-6121. (Pubitemid 28535982)
11. Guerrini, M. M., C. Sobacchi, B. Cassani, M. Abinun, S. S. Kilic, A. Pangrazio, D. Moratto, E. Mazzolari, J. Clayton-Smith, P. Orchard, et al. 2008. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am. J. Hum. Genet. 83: 64-76. (Pubitemid 351916706)
12. McClung, M. R., E. M. Lewiecki, S. B. Cohen, M. A. Bolognese, G. C. Woodson, A. H. Moffett, M. Peacock, P. D. Miller, S. N. Lederman, C. H. Chesnut, et al AMG 162 Bone Loss Study Group. 2006. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354: 821-831. (Pubitemid 43290920)
13. Lipton, A., G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J. J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al. 2007. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25: 4431-4437. (Pubitemid 350013849)
14. Bone, H. G., M. A. Bolognese, C. K. Yuen, D. L. Kendler, H. Wang, Y. Liu, and J. San Martin. 2008. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93: 2149-2157. (Pubitemid 351831529)
15. Cohen, S. B., R. K. Dore, N. E. Lane, P. A. Ory, C. G. Peterfy, J. T. Sharp, D. van der Heijde, L. Zhou, W. Tsuji, and R. Newmark; Denosumab Rheumatoid Arthritis Study Group. 2008. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58: 1299-1309. (Pubitemid 351705919)
16. Miller, P. D., M. A. Bolognese, E. M. Lewiecki, M. R. McClung, B. Ding, M. Austin, Y. Liu, and J. San Martin; Amg Bone Loss Study Group. 2008. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43: 222-229.
17. Brown, J. P., R. L. Prince, C. Deal, R. R. Recker, D. P. Kiel, L. H. de Gregorio, P. Hadji, L. C. Hofbauer, J. M. Alvaro-Gracia, H. Wang, et al. 2009. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24: 153-161.
18. Cummings, S. R., J. San Martin, M. R. McClung, E. S. Siris, R. Eastell, I. R. Reid, P. Delmas, H. B. Zoog, M. Austin, A. Wang, et al FREEDOM Trial. 2009. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361: 756-765.
19. Smith, M. R., B. Egerdie, N. Hernández Toriz, R. Feldman, T. L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, et al; Denosumab HALT Prostate Cancer Study Group. 2009. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361: 745-755.
20. Sobacchi, C., A. Frattini, M. M. Guerrini, M. Abinun, A. Pangrazio, L. Susani, R. Bredius, G. Mancini, A. Cant, N. Bishop, et al. 2007. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39: 960-962. (Pubitemid 47185178)
21. Hanada, R., A. Leibbrandt, T. Hanada, S. Kitaoka, T. Furuyashiki, H. Fujihara, J. Trichereau, M. Paolino, F. Qadri, R. Plehm, et al. 2009. Central control of fever and female body temperature by RANKL/RANK. Nature 462: 505-509.
22. Hobeika, E., S. Thiemann, B. Storch, H. Jumaa, P. J. Nielsen, R. Pelanda, and M. Reth. 2006. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl. Acad. Sci. USA 103: 13789-13794. (Pubitemid 44413986)
23. Perlot, T., F. W. Alt, C. H. Bassing, H. Suh, and E. Pinaud. 2005. Elucidation of IgH intronic enhancer functions via germ-line deletion. Proc. Natl. Acad. Sci. USA 102: 14362-14367. (Pubitemid 41429703)
24. Perlot, T., I. Pawlitzky, J. P. Manis, A. A. Zarrin, P. H. Brodeur, and F. W. Alt. 2010. Analysis of mice lacking DNaseI hypersensitive sites at the 5′ end of the IgH locus. PLoS ONE 5: e13992.
25. Matthias, P., and A. G. Rolink. 2005. Transcriptional networks in developing and mature B cells. Nat. Rev. Immunol. 5: 497-508. (Pubitemid 40835037)
26. Kim, D., R. E. Mebius, J. D. MacMicking, S. Jung, T. Cupedo, Y. Castellanos, J. Rho, B. R. Wong, R. Josien, N. Kim, et al. 2000. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J. Exp. Med. 192: 1467-1478.